# Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

> **NCT05095376** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **NRG Oncology** · enrollment: 265 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **DRUG:** Lomustine
- **PROCEDURE:** Magnetic Resonance Imaging
- **RADIATION:** Photon Beam Radiation Therapy
- **OTHER:** Questionnaire Administration
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05095376
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-28
- **Primary completion:** 2026-08-08
- **Final completion:** 2026-08-08
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05095376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05095376, "Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05095376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*